Maternal asthma medication use and the risk of gastroschisis

American Journal of Epidemiology

Volumn 168, Issue 1, 2008, Pages 73-79

  Lin, Shao ^a   Munsie, Jean Pierre W ^a   Herdt Losavio, Michele L ^a   Bell, Erin ^b   Druschel, Charlotte ^a   Romitti, Paul A ^c   Olney, Richard ^d  

^a NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Anti inflammatory agents; Asthma; Bronchodilator agents; Gastroschisis

Indexed keywords

ADRENALIN; ANTIINFLAMMATORY AGENT; BECLOMETASONE; BRONCHODILATING AGENT; BUDESONIDE; CROMOGLYCATE DISODIUM; EPHEDRINE; FLUTICASONE; FOLIC ACID; IPRATROPIUM BROMIDE; METHYLPREDNISOLONE; MONTELUKAST; PIRBUTEROL; PREDNISOLONE; PREDNISONE; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE; TRIAMCINOLONE; VASOACTIVE AGENT; VITAMIN; ZAFIRLUKAST;

ASTHMA; DIGESTIVE SYSTEM DISORDER; DISEASE TREATMENT; DRUG; ETHNICITY; HEALTH RISK; PREGNANCY; REGRESSION ANALYSIS; RISK FACTOR; SMOKING;

ADULT; ARTICLE; ASTHMA; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DELIVERY; DISEASE ASSOCIATION; DISEASE SEVERITY; ETHNICITY; FEMALE; GASTROSCHISIS; HUMAN; INFANT; LIVE BIRTH; LOGISTIC REGRESSION ANALYSIS; MALE; MATERNAL AGE; MEDICAL INFORMATION; PATIENT EDUCATION; PRENATAL DRUG EXPOSURE; RACE; RISK; RISK FACTOR; SMOKING; STATISTICAL SIGNIFICANCE; VITAMIN INTAKE;

ADULT; ANTI-INFLAMMATORY AGENTS; ASTHMA; BRONCHODILATOR AGENTS; CASE-CONTROL STUDIES; FEMALE; GASTROSCHISIS; HUMANS; INFANT, NEWBORN; INTERVIEWS AS TOPIC; LIFE STYLE; LOGISTIC MODELS; MALE; MATERNAL WELFARE; MATERNAL-FETAL EXCHANGE; PREGNANCY; PREGNANCY COMPLICATIONS; UNITED STATES;

EID: 45849135947     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwn098     Document Type: Article

References (27)

1. Kwon HL, Belanger K, Bracken MB. Asthma prevalence among pregnant and childbearing-aged women in the United States: estimates from national health surveys. Ann Epidemiol 2003;13:317-24.
2. NAEPP Expert Panel report. Managing asthma during pregnancy: recommendations for pharmacologic treatment - 2004 update. J Allergy Clin Immunol 2005;115:34-46.
3. Kallen B, Olausson PO. Use of anti-asthmatic drugs during pregnancy. 3. Congenital malformations in the infants. Eur J Clin Pharmacol 2007;63:383-8.
4. Proventil, brand of albuterol, USP. In: Physicians' desk reference. 53rd ed. Montvale, NJ: Medical Economics Company, 2006:3067-9.
5. Park JM, Schmer V, Myers TL. Cardiovascular anomalies associated with prenatal exposure to theophylline. South Med J 1990;83:1487-8.
6. Demissie K, Breckenridge MB, Rhoads GG. Infant and maternal outcomes in the pregnancies of asthmatic women. Am J Respir Crit Care Med 1998;158:1091-5.
7. Rosa F. Databases in the assessment of the effects of drugs during pregnancy. J Allergy Clin Immunol 1999;103(2 pt 2):S360-1.
8. Namazy JA, Schatz M. Update in the treatment of asthma during pregnancy. Clin Rev Allergy Immunol 2004;26:139-47.
9. Briggs GG, Freeman RA, Yaffe SJ. Michigan Medicaid study. Drugs in pregnancy and lactation. 4th ed. Baltimore, MD: Williams and Wilkins, 1994.
10. Liu S, Wen SW, Demissie K, et al. Maternal asthma and pregnancy outcomes: a retrospective cohort study. Am J Obstet Gynecol 2001;184:90-6.
11. Hunter A, Soothill P. Gastroschisis - an overview. Prenat Diagn 2002;22:869-73.
12. Rankin J, Dillon E, Wright C. Congenital anterior abdominal wall defects in the north of England, 1986-1996: occurrence and outcome. Prenat Diagn 1996;19:662-8.
13. Suita S, Okamatsu T, Yamamoto T, et al. Changing profile of abdominal wall defects in Japan: results of a national survey. J Pediatr Surg 2000;35:66-71.
14. Werler MM, Mitchell AA, Shapiro S. Demographic, reproductive, medical, and environmental factors in relation to gastroschisis. Teratology 1992;45:353-60.
15. Goldbaum G, Daling J, Milham S. Risk factors for gastroschisis. Teratology 1990;42:397-403.
16. Werler MM, Mitchell AA, Shapiro S. First trimester maternal medication use in relation to gastroschisis. Teratology 1992;45:361-7.
17. Werler MM, Sheehan JE, Mitchell AA. Association of vasoconstrictive exposures with risks of gastroschisis and small intestinal atresia. Epidemiology 2003;14:349-54.
18. Torfs CP, Katz EA, Bateson TF, et al. Maternal medications and environmental exposures as risk factors for gastroschisis. Teratology 1996;54:84-92.
19. Feldkamp ML, Carey JC, Sadler TW. Development of gastroschisis: review of hypotheses, a novel hypothesis, and implications for research. Am J Med Genet A 2007;143:639-52.
20. Johnson TRB, Niebyl JR. Preconception and prenatal care: part of the continuum. In: Gabbe SG, Niebyl JR, Simpson JL, eds. Obstetrics: normal and problem pregnancies. Philadelphia, PA: Churchill Livingstone, 2002:1038-46.
21. Danielsson BR, Skold AC, Johansson A, et al. Teratogenicity by the hERG potassium channel blocking drug almokalant: use of hypoxia marker gives evidence for a hypoxia-related mechanism mediated via embryonic arrhythmia. Toxicol Appl Pharmacol 2003;193:168-76.
22. Yoon PW, Rasmussen SA, Lynberg MC, et al. The National Birth Defects Prevention Study. Public Health Rep 2001;116(suppl 1):32-40.
23. Rasmussen SA, Olney RS, Holmes LB, et al. Guidelines for case classification for the National Birth Defects Prevention Study. Birth Defects Res A Clin Mol Teratol 2003;67:193-201.
24. Osur SL. The management of asthma and rhinitis during pregnancy. J Womens Health (Larchmt) 2005;14:263-76.
25. Lipworth BJ. Fortnightly review: modern drug treatment of chronic asthma. BMJ 1999;318:380-4.
26. Bracken MB, Triche EW, Belanger K, et al. Asthma symptoms, severity, and drug therapy: a prospective study of effects on 2205 pregnancies. Obstet Gynecol 2003;102:739-52.
27. Mitchell AA. Systematic identification of drugs that cause birth defects: a new opportunity. N Engl J Med 2003;349:2556-9.